Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX GmbH has been awarded a grant from the Federal Ministry of Education and Research (BMBF) to develop an immuno-oncology test.

March 1, 2017


2cureX’s German subsidiary 2cureX GmbH has received funding (EUR 810.000) from Federal Ministry of Education and Research (BMBF, Berlin) to direct 2cureX’s IndiTreat™ test towards the immuno-oncology area. There is a tremendous focus on strengthening the immune system’s ability to combat cancer. It is however a limited proportion of patients with solid cancers that will benefit from such treatment. It is therefore of paramount importance to develop technologies that can select the sensitive patients. 2cureX will in collaboration with University Medical Center Hamburg-Eppendorf (UKE) develop an IndiTreat™ test for matching the right immuno-oncological treatment with the sensitive patient.